What type of study is this?

This is a Meta-Analysis study (also classified as: Systematic Review).

What question did this study set out to answer?

To assess adherence patterns, participation, FIT-positivity, and neoplasia detection in fecal immunochemical test-based colorectal cancer screening.

February 22, 2026

Systematic review of participation, positivity and yield over time in fecal immunochemical test-based organized colorectal cancer screening programs

Puntos clave

To assess adherence patterns, participation, FIT-positivity, and neoplasia detection in fecal immunochemical test-based colorectal cancer screening.
Conducted systematic review and meta-analysis across multiple databases
Identified adherence patterns among screening participants
Evaluated per-round participation and positivity rates for CRC and adenomas
Overall participation ranged from 51.3% to 56.9% across screening rounds
FIT-positivity decreased from 6.6% in the first round to 5.3% by the fourth round
Positive predictive values for CRC and AA were highest in initial screening rounds

Resumen

Fecal immunochemical testing (FIT), the most common colorectal cancer (CRC) screening modality worldwide, requires programmatic participation over decades. We performed a systematic review and meta-analysis to ascertain overall adherence patterns, per-round participation, FIT-positivity, and neoplasia detection rates in organized FIT-based screening programs, contrasting initial vs. subsequent screening rounds. We systematically searched Pubmed, Embase and Cochrane databases. Adherence patterns were defined as consistent screeners (all rounds), intermittent screeners, and never attendants. Per-round participation, FIT-positivity, and positive predictive values (PPVs) for CRC, advanced adenoma (AA), and adenoma were determined overall and for consistent screeners. Subgroup analyses were performed by screening periodicity and FIT positivity cut-off. Of 4,414 candidate studies, 24 were included. Adherence patterns were: 47.1% (SD 11.6) consistent screeners, 22.7% (SD 4.7) intermittent screeners, and 30.3% (SD 12.2) never attendants. Overall pooled results from the first through fourth rounds showed per-round participation of 51.3 (95% CI 37.4-65.3)%, 56.7 (41.3-72.2)%, 56.9 (38.7-75.3)%, and 56.5 (44.-68.6)%; FIT-positivity of 6.6 (5.9-7.3)%, 5.6 (4.6-6.6)%, 5.3 (4.0-6.6)%, and 5.3 (3.7-6.9)%; CRC PPV of 5.8 (4.1-7.4)%, 3.3 (2.3-4-3)%, 2.9 (2.2-3.7)%, and 2.5 (1.4-3.5)%; AA PPV of 32.8 (23.5-42.0)%, 28.3 (21.8-34.7)%, 22.7 (16.5-28.9)%, and 23 (10.1-35.9)%; and adenoma PPV of 48.6 (45.8-51.4)%, 46.2 (42.4-50.1)%, 48.7 (43.9-53.6)%, and 44.6 (38.2-51.0)%, respectively. Similar trends were observed for consistent screeners and for biennial FIT with 20μg Hb/g feces positivity cut-off. Organized FIT-based CRC screening programs achieve consistent participation in nearly half of persons and no participation in approximately one third. FIT-positivity and yields for CRC, AA, and adenoma are highest in the first round and may stabilize at clinically relevant steady states at the third to fourth rounds.

Preguntar a la IA

Me gusta

Guardar